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The pharmacokinetics (PK), biodistribution (BD), and therapeutic activity of pegylated liposomal doxorubicin formulations with different
drug release rates were studied in an orthotopic 4T1 murine mammary carcinoma model. The focus of these experiments was to study the
effects of different release rates on the accumulation of liposomal lipid and doxorubicin (DXR) into the tumor and cutaneous tissues of mice
(skin and paws). These tissues were chosen because the clinical formulation of pegylated liposomal doxorubicin (CaelyxR/DoxilR) causes
mucocutaneous reactions such as palmar-plantar erythrodysesthesia (PPE). Liposomes with different doxorubicin (DXR) leakage rates were
prepared by altering liposome fluidity through changing the fatty acyl chain length and/or degree of saturation of the phosphatidylcholine
component of the liposome. Liposomes with fast, intermediate, and slow rates of drug release were studied. The plasma PK of the liposomal
lipid was similar for all formulations, while the plasma PK of the DXR component was dependent on the liposome formulation. Liposomal
lipid accumulated to similar levels in tumor and cutaneous tissues for all three formulations tested, while the liposomes with the slowest rates
of DXR release produced the highest DXR concentrations in both cutaneous tissues and in tumor. Liposomes with the fastest drug release
rates resulted in low DXR concentrations in cutaneous tissues and tumor. The formulation with intermediate release rates produced
unexpected toxicity that was not related to the lipid content of the formulation. The liposomes with the slowest rate of drug leakage had the
best therapeutic activity of the formulations tested.
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1. Introduction in animal models of cancer [1–3]. Small diameters and longDrug release rates, liposome diameter and circulation
half-life play an important role in determining the therapeu-
tic activity and toxicity of liposomal drug delivery systems0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: terry.allen@ualberta.ca (T.M. Allen).circulation half-lives allow liposomal drugs to accumulate in
tissues with increased vascular permeability (e.g., tumor
tissue), but only if liposomes retain their drug load over
several hours to days will high drug concentrations accu-
mulate in tumor tissues [4]. After liposomes have localized
to tumors, the drug must be released, i.e., become bioavail-
able, in order to exert its biological effects. However, if
liposomes release their drug content at a rate that is rapid
compared to the rate of tissue accumulation, then their
therapeutic activity may be compromised. In this paper,
we have examined the effect of different drug release rates
on the accumulation of liposomal lipid and liposomal
contents (doxorubicin, DXR) in mucocutaneous tissues
and tumors in orthotopic murine breast cancer models.
Clinically, the importance of the drug release rate for the
pharmacokinetics (PK) and toxicity of liposomal formula-
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(DoxilR in the United States) and Myocetk, two liposomal
formulations of doxorubicin (DXR) (reviewed in Ref. [5]).
CaelyxR is a STEALTHR liposomal formulation of DXR;
its rigid bilayer is composed of fully hydrogenated soy
phosphatidylcholine (HSPC), cholesterol (CHOL), and
methoxypolyethyene glycol (Mr 2000)-distearoylphosphati-
dylethanolamine (mPEG-DSPE) at a molar ratio of 55:40:5
[6]. Myocetk is composed of egg yolk phosphatidylcholine
and CHOL at a molar ratio of 55:45 and has a fluid bilayer
[7]. The different lipid compositions of these two formula-
tions are primarily responsible for the differences in the PK of
the encapsulated DXR. Myocetk has a much faster rate of
drug release than CaelyxR, as evidenced by the much shorter
half life (6.7 vs. 45 h) and larger volume of distribution of
DXR released from Myocetk (18.8 vs. 4.1 l) [7,8]. The PK
of the encapsulated DXR, in turn, influences the toxicity
profile of each formulation. Compared to conventionally
administered DXR, both liposome formulations show re-
duced cardiac toxicity [9,10]. The acute dose-limiting toxic-
ity of the Myocetk formulation is myelosuppression, similar
to that of conventionally administered DXR [7]. CaelyxR has
a low incidence of myelosuppression and its dose-limiting
toxicities are mucocutaneous reactions such as stomatitis and
palmar-plantar erythrodysesthesia (PPE) [11,12]. Clinically,
the incidence of PPE is related to the dose intensity of
CaelyxR therapy, with an increased incidence in patients
receiving >10–12 mg/m2/week [12,13]. CaelyxR-induced
PPE develops primarily on the hands and feet and can lead to
severe pain and blistering desquamation [11,12,14]. PPE is
hypothesized to develop as DXR-loaded liposomes localize
to cutaneous tissues and slowly release DXR, which then
damages the basal layers of the skin. Current attempts to
reduce the incidence and severity of PPE have not proven
effective; using a murine model to develop a better under-
standing of the mechanisms underlying this toxicity may lead
to newer strategies to reduce this painful toxicity [15,16].
CaelyxR has dose-independent, log-linear PK (reviewed
in Ref. [17]), small size (100 nm diameter), slow rates of
drug release and long circulation times allowing it to
extravasate into diseased tissues through the ‘enhanced
permeability and retention’ or EPR effect [18,19]. Conse-
quently, CaelyxR, or liposomes with similar properties,
mediate accumulation of encapsulated drugs in solid tumors,
which has translated into improved therapeutic activity
relative to free (non-encapsulated) drugs [20,21]. However,
long-circulating liposomes also accumulate in the cutaneous
tissues of experimental animals to a greater extent than
formulations with shorter half-lives, supporting the hypoth-
esis that cutaneous accumulation of drug-loaded liposomes
underlies the development of PPE [22–25].
Previous work from our laboratory in the 4T1 murine
mammary carcinoma model demonstrated that liposomes
accumulate in tumor tissue at higher concentrations and at a
faster rate than in cutaneous tissues such as skin and paws
[26]. Peak skin and paw DXR levels occurred as long as 48h after peak tumor DXR levels. These findings led to the
hypothesis that the DXR concentration in cutaneous tissues,
relative to tumor DXR levels, could be reduced if the rate of
liposomal drug release was increased. By manipulating drug
release rates, it may thus be possible to reduce cutaneous
toxicities without affecting the therapeutic activity of pegy-
lated liposomal doxorubicin.
To explore this hypothesis, we prepared pegylated lipo-
somal formulations of DXR with different rates of drug
release. Fatty acyl chain length and saturation are important
determinants of liposomal drug retention in vivo and in vitro
[1,27,28]. Hence, pegylated liposomes with faster, interme-
diate, and slower rates of DXR leakage were formulated by
altering the fatty acyl chain length and degree of saturation
of phosphatidylcholine, the bilayer-forming element in the
liposomes. The PK, biodistribution (BD), and therapeutic
activity of the three formulations was examined in the 4T1
murine mammary carcinoma model.2. Materials and methods
2.1. Materials
CaelyxR/DoxilR (STEALTHR liposomal doxorubicin),
doxorubicin hydrochloride (DXR), and methoxypolyethyle-
neglycol (Mr 2000)-distearoylphosphatidylethanolamine
(mPEG2000-DSPE) were from ALZA Corporation (Moun-
tain View, CA). Dimyristoylphosphatidylcholine (DMPC),
dioleoylphosphatidylcholine (DOPC), distearoylphosphati-
dylcholine (DSPC), palmitoyl-myristoylphosphatidylcholine
(PMPC), palmitoyl-oleoylphosphatidylcholine (POPC),
stearoyl-myristoylphosphatidylcholine (SMPC), and choles-
terol (CHOL) were purchased from Avanti Polar Lipids
(Alabaster, AL). Sephadex-G50 was from Amersham-Phar-
macia Biotech (Baie d’Urfe, PQ, Canada). Minimal essential
medium (MEM) was from Sigma Chemical Company (St.
Louis, MO) and fetal bovine serum (FBS), penicillin, and
streptomycin were from Life Technologies Inc. (Burlington,
ON, Canada). Halothane was from MTC Pharmaceuticals
(Cambridge, ON, Canada). Sterile, pyrogen-free saline was
purchased from Baxter (Toronto, ON, Canada), and sterile
saline was supplemented with 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, pH 7.4 (HEPES-buffered sa-
line; HBS). 3H-Cholesteryl hexadecylether (3H-CHE) was
from Perkin Elmer Biosciences (Boston, MA). Solvable and
Ultima Gold were from Perkin Elmer Life Sciences (Wood-
bridge, ON, Canada). All other chemicals were of the highest
grade possible.
2.2. Liposome preparation
All liposomal formulations were composed of the bilay-
er-forming phospholipid phosphatidylcholine, with fatty
acyl chains of various lengths and degrees of saturation,
in combination with CHOL (2:1 molar ratio) and contained
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osomes were prepared by the thin film hydration technique,
and DXR was remote-loaded using an ammonium sulfate
gradient as previously described [29,30]. Briefly, dried lipid
films were hydrated with 250 mM ammonium sulfate.
Using a Lipex Extruder (Northern Lipids, Vancouver, BC,
Canada), the lipid mix was extruded through stacked
Nuclepore filters to yield small unilamellar vesicles. The
temperature of extrusion depended on the phosphatidylcho-
line component of the mixture. Fluid lipids whose phase
transition temperatures are below room temperature (POPC,
DOPC) were extruded at room temperature; other lipids
were also extruded slightly above their phase transition
temperatures (DSPC was extruded at 65 jC, SMPC and
PMPC were extruded at 35 jC, and DMPC was extruded at
30 jC). Liposomes were sized by dynamic light scattering
using a Brookhaven BI-90 Particle Sizer (Brookhaven
Instruments, Holtsville, NY). All liposomes had a mean
diameter of 100F 20 nm. After sizing, the external buffer
was exchanged by passage over a Sephadex G-50 column in
sodium acetate buffer (pH 5.5). DXR in 10% sucrose (wt/
vol) was then incubated with the liposomes at a 0.2:1 (wt/
wt) drug to lipid ratio. Small amounts of residual non-
encapsulated DXR were removed by passage over a Sepha-
dex G-50 column equilibrated with HBS, pH 7.4. For PK
and BD experiments, the non-exchanged, non-metabolized
lipid marker 3H-CHE (2 ACi/Amol lipid) was incorporated
into the lipid film. Lipid concentrations were determined by
using the specific activity of 3H-CHE, and DXR concen-
trations were calculated from the absorption at 480 nm in
methanol by comparison to a standard curve.
2.3. In vitro release rate of DXR in serum
The in vitro leakage of DXR from liposomes was
measured using a dialysis method. Liposomes, at a concen-
tration of 0.5 mM phospholipid, were diluted in 50% adult
bovine serum (ABS) in HBS, pH 7.4, placed in a dialysis
cassette with a molecular weight cutoff of 10 kDa, and
dialyzed against 200 ml of 50% ABS containing penicillin
(100 units/ml) and streptomycin (100 Ag/ml) at 37 jC [31].
ABS was used instead of human plasma as a source of
plasma proteins due to difficulties in obtaining human
plasma. The concentration of lipid was selected to approx-
imate the liposome concentration expected in the blood
compartment of a 20-g mouse receiving liposomal DXR at
a dose of 5–6 mg DXR/kg body weight. At various time
points, aliquots were withdrawn from the cassette and stored
at 4 jC until analysis. Total DXR concentration, including
possible fluorescent metabolites, was measured by fluores-
cence at kex 470, kem 590 in methanol acidified with 0.075
N HCl, as previously described [21] using a SLM-AMINCO
Model 8100 Series 2 Spectrometer (Spectronics Instruments
Inc., Rochester, NY). The results were plotted as log percent
of initial fluorescence versus time, and the t1/2 was calcu-
lated using the regression line from the linear portion of thecurve; r2 values for these lines were greater than 0.926
(range 0.926–0.994).
2.4. Tumor implantation
Female BALB/c cr Alt BM mice (6–8 weeks) were
purchased from the breeding colony at the University of
Alberta’s Health Sciences Laboratory Animal Services.
Mice were housed under standard conditions and had access
to food and water ad libitum. All protocols were approved
by the Health Sciences Animal Policy and Welfare Com-
mittee, University of Alberta, and are in accordance with the
Guide to the Care and Use of Experimental Animals set
forth by the Canadian Council on Animal Care.
The 4T1 murine mammary carcinoma, a metastatic,
thioguanine-resistant cell line, was a generous gift from
Dr. Fred Miller (Barbara Ann Karmanlos Cancer Institute,
Detroit, MI) [32]. The cell line was maintained in MEM
supplemented with 10% FBS, penicillin (100 units/ml), and
streptomycin (100 Ag/ml) at 37 jC in a humidified incubator
with a 5% CO2 atmosphere. Tumors were orthotopically
implanted as previously described [33]. Briefly, mice were
anesthetized with halothane, the lower abdomen was
shaved, and a small incision (6–8 mm) was made adjacent
to the mid-line. The right #4 mammary fat pad was exposed,
and 105 cells in 10-Al media were implanted. The wound
was closed with a surgical wound clip that was removed 7
days later.
2.5. Pharmacokinetic and biodistribution studies
In initial experiments, the plasma total DXR concentra-
tions, which included possible fluorescent metabolites, were
determined 4 h after injection of various liposomal formu-
lations of DXR in naı¨ve mice. The tested formulations were
DSPC:CHOL:mPEG-DSPE, SMPC:CHOL:mPEG-DSPE,
POPC:CHOL:mPEG-DSPE, PMPC:CHOL:mPEG-DSPE,
DOPC:CHOL:mPEG-DSPE, and DMPC:CHOL:mPEG-
DSPE, all at a 2:1:0.1 molar ratio, and CaelyxR. Female
BALB/c mice (6–8 weeks) were injected with 6 mg DXR/
kg (18 mg/m2) as liposomal DXR, prepared as above. Four
hours after injection, mice were euthanized by halothane
anesthesia followed by cervical dislocation. Whole blood
was collected via cardiac puncture using a heparinized
syringe, and plasma prepared by centrifugation at
3000 g for 5 min. DXR concentrations were determined
as described below.
In other experiments, mice were implanted with the 4T1
murine mammary carcinoma as described above. Ten days
after tumor implantation, when the tumors were large
enough to excise, mice were injected with 6 mg DXR/kg
(18 mg/m2) liposomal doxorubicin with varying drug re-
lease rates (DSPC:CHOL:mPEG-DSPE, POPC:CHOL:
mPEG-DSPE, or DOPC:CHOL:mPEG-DSPE at 2:1:0.1
molar ratios). At various time points after injection (1, 12,
24, 48, 72, 168 h), mice (five per group) were euthanized,
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scribed in Section 2.6. The area under the plasma or tissue
concentration-versus-time curve (AUC) was calculated us-
ing the trapezoidal rule with extrapolation to infinity, and t1/2
was calculated using the formula t1/2 = 0.693/kelm, where kelm
is the elimination constant derived from the best-fit line of
the data plotted on a semi-log plot. Clearance (CL) was
calculated using the formula CL= dose/AUC0–l [34]. Vd
was estimated by dividing the injected dose by the plasma
concentration extrapolated back to time zero using all five
data points for DSPC:CHOL:mPEG-DSPE and POPC:-
CHOL:mPEG-DSPE liposomes and the first three data
points for DOPC:CHOL:mPEG-DSPE liposomes.
2.6. Determination of doxorubicin and liposomal lipid
For PK and BD experiments, total doxorubicin and
liposomal lipid were quantified using a method similar to
the one described by Harasym et al. [35]. Tissue homoge-
nates (10% wt/vol) were prepared in water using a Polytron
homogenizer (Brinkman Instruments, Mississauga, ON,
Canada). Dorsal skin samples and samples of paws from
below the wrist joint were first frozen in liquid nitrogen and
pulverized with a pestle and mortar before homogenization.
Plasma was prepared as described above. Homogenates
(200 Al) or 25% plasma in water (200 Al) was extracted
overnight at  25 jC by adding first 100-Al 10% Triton-X
100 and 200-Al water and then 1500-Al acidified isopropa-
nol (0.75 N HCl) [21]. The next day, the tubes were warmed
to room temperature, vortexed for 5 min, spun at 15,000 g
for 20 min, and stored at  80 jC until analysis. Total DXR
was quantified spectrofluorometrically at kex 470 nm and
kem 590 nm. To correct for background fluorescence, a
standard curve was obtained by spiking tissue extracts
derived from mice that had not received drug with DXR.
This method was shown to recover on average >90% of
DXR-associated fluorescence. Tissue concentrations of
DXR were expressed as microequivalents per milliliter of
plasma or per gram of tissue, as this assay does not
discriminate between doxorubicin and any fluorescent
metabolites with similar excitation and emission profiles
that may have been present.
Liposomal lipid was quantitated using a method similar
to the one described by Harasym et al. [35], using the non-
exchangeable and non-metabolizeable lipid marker 3H-CHE
at a concentration of 2 ACi/Amol total lipid as a tracer.
Briefly, 500 Al of SolvableR was added to 200 Al of
homogenate or 50 Al of plasma. The solutions were then
digested for 2 h at 60 jC. After the vials had cooled to room
temperature, 50 Al of 200 mM EDTA was added, and the
samples were bleached overnight with 200 Al of hydrogen
peroxide (30% vol/vol). The next day, 100 Al of 1 N HCl
and 5 ml of Ultima Gold scintillation fluor were added in
sequence, and the samples were counted in a Beckman LS
6500 liquid scintillation counter. Lipid concentrations are
expressed as micrograms of total lipid per milliliter ofplasma or per gram of tissue. For both liposomal lipid and
DXR, values given represent the meanF S.D. of triplicate
samples from five mice.
2.7. Tumor growth delay studies
Mice were implanted with the 4T1 tumor as described
above. Four days after tumor implantation, groups of six
mice were injected intravenously with liposomal DXR (6
mg DXR/kg, 18 mg/m2) composed either of DSPC:
CHOL:mPEG-DSPE, POPC:CHOL:mPEG-DSPE, or
DOPC:CHOL:mPEG-DSPE (2:1:0.1 molar ratio); control
mice received 200 Al of sterile saline. Because the 4T1
tumor grows very rapidly, mice were treated 4 days after
tumor implantation when tumors were just palpable, instead
of after 10 days as in the PK and BD experiments. Tumor
growth was measured using calipers, and volume was
calculated using the formula v = 0.4ab2 where a and b are
perpendicular diameters and a>b [33]. The values given
represent the mean tumor volumeF S.D. from two separate
experiments.
2.8. Statistics
Statistical comparisons were performed using a multiple-
comparison ANOVA assay with a Tukey–Krammer post
test with Graph Pad InStat Version 3.01 for Windows 95/NT
(GraphPad Software, San Diego CA).3. Results
3.1. In vitro leakage of DXR from liposomes
The results of in vitro DXR leakage experiments are
presented in Table 1. Incorporating phosphatidylcholines
with lower phase transition temperature into the liposomal
membrane (i.e., lipids with unsaturated and/or shorter fatty
acyl chains) increased drug leakage rates compared to lip-
osomes containing lipids with higher phase transition tem-
peratures. Based on the in vitro data, a range of formulations
was used for in vivo studies.
3.2. Plasma doxorubicin concentrations 4 h after injection
Based on the data presented in Table 2, three liposome
compositions were selected for in vivo testing. To determine
in vivo drug retention of those liposome formulations,
plasma DXR concentrations were determined in naı¨ve
BALB/c mice at 4 h after injection of 6 mg DXR/kg as
liposomal DXR. Plasma levels provide a good measure of
drug retention, since DXR released in plasma rapidly redis-
tributes to other tissues (greater than 95% of circulating
DXR is entrapped within STEALTHR liposomes [8,36]). In
our experiments, liposomes were composed of DSPC,
SMPC, POPC, DOPC, or DMPC with 50 mol% CHOL
Table 1
Leakage half-lives of DXR from liposomes
Lipid composition Phase transition
temperature of
phosphatidylcholine
(jC)
Ratio
(mol)
n t1/2 (h)
Caelyx
(HSPC:CHOL:mPEG)
55 55:40:5 5 118.4F 18.8
HSPC:CHOL:mPEG 55 2:1:0.1 5 91.8F 11.2
DMPC:CHOL:mPEG 23 2:1:0.1 4 23.0F 6.4
POPC:CHOL:mPEG  2 2:1:0.1 2 14.6, 11.9
DOPC:CHOL:mPEG  20 2:1:0.1 2 14.9, 10.2
Liposomes (0.5 mM phospholipid) were placed inside a dialysis cassette
(MW cutoff 10 kD) and incubated at 37 jC in adult bovine serum in HBS,
pH 7.4 (50% v/v). At various time points, aliquots were withdrawn, and the
DXR was extracted in acidified methanol and measured fluorometrically.
Data were then plotted on a semi-log scale as percent of initial fluorescence
vs. time. Half-lives were determined from the linear portion of each curve
by using regression analysis. Half-lives represent the meanF S.D. of n
experiments; for n < 3, the individual half-lives are given for each
experiment.
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used instead of HSPC as it has a similar phase transition
temperature to HSPC; CaelyxR was tested as well. Lip-
osomes that contained phosphatidylcholines with long,Fig. 1. Plasma concentrations of DXR (panel A), liposomal lipid (panel B), and nor
mammary carcinoma were injected with 6 mg/kg liposomal DXR and 30 mg/kg
DOPC:CHOL:mPEG-DSPE at a molar ratio of 2:1:0.1) 10 days after tumor im
represent the meanF S.D. from triplicate samples from five mice per time point. D
injected liposomes.saturated fatty acyl chains had a more rigid bilayer, and
gave rise to higher plasma DXR concentrations at 4 h after
injection than more fluid DXR-loaded liposomes. Based on
these results, liposomes with faster (DOPC:CHOL:mPEG-
DSPE), intermediate (POPC:CHOL:mPEG-DSPE) and
slower (DSPC:CHOL:mPEG-DSPE) rates of drug release
were chosen for further study in tumor-bearing mice.
3.3. Pharmacokinetic and biodistribution experiments in
tumor-bearing mice
Plasma concentrations of DXR and liposomal lipid, and
also drug to liposomal lipid ratios, are presented in Fig. 1 for
tumor-bearing mice receiving various formulations of lipo-
somal DXR. Liposomes composed of DSPC:CHOL:mPEG-
DSPE (slower release) achieved the highest plasma concen-
tration of DXR (Fig. 1A), which was similar to that we have
previously reported for CaelyxR [37]. Liposomes composed
of POPC:CHOL:mPEG-DSPE had intermediate release and
DOPC:CHOL:mPEG-DSPE liposomes had the fastest re-
lease. PK parameters given in Table 3 demonstrate that, for
DSPC-containing liposomes, the plasma t1/2 for DXR was
longest and approximated that of the liposomal lipid.
Further, the DSPC liposomes showed the slowest rate ofmalized drug to lipid ratios (panel C). BALB/c mice bearing the 4T1 murine
lipid (., DSPC:CHOL:mPEG-DSPE; n, POPC:CHOL:mPEG-DSPE; E,
plantation. Drug and lipid were quantified as detailed in text. The results
rug to lipid ratios in plasma were normalized to the drug to lipid ratio of the
G.J.R. Charrois, T.M. Allen / Biochimica et Biophysica Acta 1663 (2004) 167–177172DXR clearance among the tested formulations, indicating
that the drug is stably retained within this formulation. The
Vd’s for DXR increased with increasing rates of drug
release, and is consistent with faster drug leakage followed
by redistribution and metabolism. Although the plasma PK
for DXR differed for each formulation, the plasma PK for
the liposomal lipid, measured using a lipid label (3H-CHE),
were similar for each formulation (Fig. 1B and Table 3),
showing comparable values for AUC, t1/2, CL, and Vd
(Table 3). Drug to lipid ratios decreased as liposome
contents were lost and were lower for the more fluid
formulations (Fig. 1C). The decrease in drug to lipid ratios
paralleled the decrease in plasma concentrations of DXR for
each formulation. In other words, for formulations with
more rapid release rates, drug-depleted liposomes are pres-
ent in circulation.
The accumulation of DXR and liposomal lipid into 4T1
mammary tumors is presented in Fig. 2. The most stable
liposomes, composed of DSPC:CHOL:mPEG-DSPE, deliv-
ered the highest amount of total DXR into tumors, leading
to tumor DXR concentrations far exceeding those achieved
with POPC:CHOL:mPEG-DSPE or DOPC:CHOL:mPEG-
DSPE liposomes (Fig. 2A). This trend is reflected in the
respective AUCs (Table 3). The time course for DXR
accumulation in tumor was also different for the three
formulations. Peak tumor DXR concentration (Cmax)
was reached at 24 h with liposomes composed ofFig. 2. Tumor concentrations of DXR (panel A), liposomal lipid (panel B) and
n POPC:CHOL:mPEG-DSPE; E DOPC:CHOL:mPEG-DSPE at a molar ratio oDSPC:CHOL:mPEG-DSPE, while Cmax was reached at 12
h for POPC:CHOL:mPEG and DOPC:CHOL:mPEG-DSPE
liposomes (Fig. 2A). The earlier time to peak concentrations
for the more leaky formulations may reflect the delivery of
some of the released drug to the tumor tissue in the free
form. In contrast, the accumulation of liposomal lipid was
similar for all three formulations, with tumor concentrations
of lipid plateauing by 24 h (Fig. 2B). The lower concentra-
tion of drug in the tumor relative to lipid for the more leaky
formulations suggests that drug-depleted liposomes were
accumulating in tumor. Liposomal lipid (i.e., radiolabelled
3H-CHE) did not appear to be substantially cleared from the
tumor over the time course of the experiments. For DXR,
gradual clearance from the tumor could be observed over
the time course of the experiment. As can be seen from the
clearance t1/2’s for DXR from tumor for the different
liposomal formulations, DSPC:CHOL:mPEG-DSPE was
the most stable, followed by the POPC and DOPC formu-
lations (Table 3).
Accumulation of total DXR and lipid into skin and paws
is shown in Figs. 3 and 4, respectively. In these tissues,
DXR concentrations peaked later and at lower levels than in
tumor. Lipid levels in skin and paws continued to increase
over several days, and lipid accumulation in these tissues
was independent of the formulation used (Table 3). Further-
more, the lipid data for both skin and paws suggest that
drug-depleted liposomes continued to accumulate in thesenormalized drug to lipid ratios (panel C). (. DSPC:CHOL:mPEG-DSPE;
f 2:1:0.1). Details as in Fig. 1.
Fig. 3. Skin concentrations of DXR (panel A), liposomal lipid (panel B) and normalized drug to lipid ratios (panel C). (. DSPC:CHOL:mPEG-DSPE;
n POPC:CHOL:mPEG-DSPE; E DOPC:CHOL:mPEG-DSPE at a molar ratio of 2:1:0.1). Details as in Fig. 1.
Fig. 4. Paw concentrations of DXR (panel A), liposomal lipid (panel B) and normalized drug to lipid ratios (panel C). (. DSPC:CHOL:mPEG-DSPE;
n POPC:CHOL:mPEG-DSPE; E DOPC:CHOL:mPEG-DSPE at a molar ratio of 2:1:0.1). Details as in Fig. 1.
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Fig. 5. Therapeutic activity of different formulations of liposomal DXR
against the 4T1 murine mammary carcinoma. BALB/c mice were implanted
in the #4 mammary fat pad with the 4T1 murine mammary carcinoma. Four
days later (arrow), mice were treated with liposomal DXR at a DXR dose of
6 mg/kg. Liposomes (2:1:0.1 mol) were composed of DSPC:CHOL:mPEG
(.), POPC:CHOL:mPEG (n), DOPC:CHOL:mPEG (E) or saline control
(x). Data represent the meanF S.D. of 5–12 mice from two pooled
experiments, except for POPC:CHOL:mPEG liposomes, where data
represent the meanF S.D. of four to six mice from one experiment.
Table 2
Plasma concentrations of total DXR achieved from various formulations of
liposomal DXR at 4 h after injection
Formulation Phase transition
temperature of
phosphatidylcholine
(jC)
Composition
(molar
ratios)
Plasma
concentration
(Aequivalent/
ml)
CaelyxR
(HSPC:CHOL:mPEG)
55 55:40:5 97.4F 11.4
DSPC:CHOL:mPEG 55 2:1:0.1 91.7F 5.8
SMPC:CHOL:mPEG 30 2:1:0.1 80.4F 4.1
POPC:CHOL:mPEG  2 2:1:0.1 63.5F 9.7
PMPC:CHOL:mPEG 27 2:1:0.1 43.2F 4.9
DOPC:CHOL:mPEG  20 2:1:0.1 18.4F 2.7
DMPC:CHOL:mPEG 23 2:1:0.1 14.2F 1.6
Mice were injected intravenously with a DXR dose of 6 mg/kg (18 mg/m2).
Values represent the meanF S.D. from three mice.
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paws were higher than in skin. For liposomes with slow and
intermediate drug release rates (DSPC and POPC-contain-
ing formulations), this translated into higher DXR concen-
trations and AUCs in paws than in skin. In contrast to DXR
clearance from tumor, the DXR tissue clearance t1/2’s for
skin and paws were similar for all three formulations (Table
3). Overall, the data presented in Table 3 demonstrate that
more solid liposomes delivered more DXR to all tissues of
interest, while equal amounts of lipid were delivered by
each formulation.
3.4. Tumor growth delay experiments
The results of the pooled experiments comparing the
therapeutic efficacy of liposomal formulations with differ-
ent leakage rates are presented in Fig. 5. Treatment of mice
with any of these formulations resulted in delayed tumor
growth. The therapeutic effect was inversely correlated
with drug release rate. The more solid liposomes contain-
ing DSPC appeared to have superior therapeutic activity
compared to more fluid formulations with more rapid drug
release rates. Fewer mice were analyzed in the POPC:-
CHOL:mPEG group due to toxicity encountered with this
formulation. In one therapeutic experiment, all the mice in
this group were euthanized due to severe weight loss
within 1 week of treatment. Administration of empty
liposomes of the same formulations resulted in no adverse
effects, however. Gross post mortem exam (performed by
the staff veterinary pathologist, University of Alberta
Health Sciences Laboratory Animal Services) revealed
blood congestion of organs, consistent with cardiovascular
toxicity. In the second therapeutic experiment with this
formulation, two mice were euthanized due to severeweight loss: One mouse had myocardial necrosis, and
the other had hepatic necrosis. No further experiments
were performed with this formulation.4. Discussion
The experiments in this study used a murine mammary
carcinoma model to compare the PK, BD, and therapeutic
activity of different formulations of liposomal DXR having
different DXR release rates. In vitro DXR leakage experi-
ments were consistent with previously published data for
DXR and other drugs, which demonstrated that the fluidity
of the liposomal membrane plays an important role in the
release of liposomal contents [3,31,36]. The only liposome
formulation for which the 4-h plasma DXR concentrations
did not parallel the in vitro results was POPC:CHOL:m-
PEG-DSPE (Tables 1 and 2). These liposomes had a short in
vitro leakage t1/2 but a higher than expected plasma DXR
concentration at 4 h after injection. This discrepancy may be
due to the differences in the composition of the adult bovine
serum and mouse blood. Other investigators have found
discrepancies between in vitro and in vivo leakage results
for other liposomal drugs, such as vincristine [38].
Results from the PK and BD experiments demonstrated
that the PK of the liposomal carrier were the same for all
formulations tested, and that long circulation times for the
carrier were independent of whether or not drug was still
present in the liposomes. This is consistent with data
demonstrating that mPEG-DPSE can impart long circulating
times on liposomes composed of fluid as well as on lip-
osomes composed of solid lipids [24,39].
The normalized drug to lipid ratios provided a measure
of drug leakage in vivo. In plasma, the decrease in this ratio
paralleled the decrease in plasma concentrations of DXR for
each formulation, suggesting that empty liposomes or lip-
osomes with low contents levels remained in circulation.
Since 3H-CHE is reported to be non-exchangeable and non-
metabolizeable, the decrease in lipid:drug ratios for at least
Table 3
Pharmacokinetic parameters for tumor-bearing mice receiving liposomal
DXR (6 mg/kg) of either DSPC:CHOL:mPEG (DSPC) POPC:CHOL:
mPEG (POPC), or DOPC:CHOL:mPEG (DOPC)
DSPC POPC DOPC
DXR 3H-CHE DXR 3H-CHE DXR 3H-CHE
Plasma
kelm 0.0380 0.0339 0.0581 0.0365 0.3266 0.0398
r2 0.983 0.977 0.971 0.989 0.981 0.974
t1/2 (h) 18.2 20.4 11.9 19.0 2.1 17.4
AUCa 3020 10600 1410 12200 430 12700
CLb 0.0020 0.0028 0.0043 0.0025 0.014 0.0024
Vd
c 0.060 0.100 0.100 0.075 0.300 0.067
Tumor
kelm 0.0097 N/A 0.0163 N/A 0.0280 N/A
r2 0.994 N/A 0.985 N/A 0.968 N/A
t1/2 (h) 71.4 N/A 42.5 N/A 24.8 N/A
AUCd 1640 20200 432 20100 193 24800
Cmax
e 18.2 150.2 6.8 182.5 4.3 132.2
Skin
kelm 0.0087 N/A 0.0083 N/A 0.0063 N/A
r2 0.936 N/A 0.996 N/A 0.811 N/A
t1/2 (h) 79.6 N/A 83.5 N/A 110 N/A
AUCd 183 2300 89 3370 107 2700
Cmax
e 1.7 23.3 0.81 23.3 1.0 30.0
Paws
kelm 0.0084 N/A 0.0092 N/A 0.0115 N/A
r2 0.997 N/A 0.986 N/A 0.969 N/A
t1/2 (h) 82.5 N/A 75.3 N/A 60.2 N/A
AUCd 588 7060 200 6560 108 6750
Cmax
e 5.3 50.2 2.0 47.7 1.2 47.3
Molar ratios for all formulations were 2:1:0.1. AUCs were calculated using
the trapezoidal rule, and plasma and tissue t1/2’s were calculated using the
formula t1/2 = 0.693/kelm, where kelm is the elimination constant derived
from the plasma or tissue concentration versus time curve; r2 represents the
coefficient of determination for this equation. (For the purposes of AUC
calculation, 1 Aequivalent is assumed to equal 1 Ag of DXR and/or
metabolites).
a Units for plasma AUC0–l are (Agh/ml).
b Units for CL are ml/h/g.
c Units for Vd are ml/g.
d Units for tissue AUC0–l are (Agh/g).
e Units for Cmax are RFU/g tissue for DXR and Ag lipid/g tissue for
liposomal lipid.
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[40]. Many liposome PK studies use gamma ray-emitting
labels such as 125I-tyraminylinulin (125I-TI) and 67Ga-des-
feroxime as surrogate markers for intact liposomes, while
other studies use lipid labels that may not be as stable as 3H-
CHE. This is often a matter of convenience since direct
measurements of drug concentrations can be difficult and
time-consuming [41,42]. As this study shows, PK and BD
studies that use a surrogate label and not the pharmacolog-
ically active agent should be interpreted with caution.
Our data demonstrate that the accumulation of liposomal
lipid (i.e., the carrier) into a given tissue (tumor, skin, or
paws) was not dependent on the formulation, whereas the
accumulation of DXR in these tissues was formulation-
dependent. The observations that tumor tissue accumulated
liposomal lipid faster and to a larger extent than skin and
paws is consistent with previous data obtained in this model
[26]. The finding that liposomal lipid concentrations were
higher in paws than in skin is also consistent with previous
data from this model and supports a pressure-dependent
extravasation of liposomes into the paws of the mice as they
walk around the cage, groom, feed, etc. [26].
Since tissue levels of liposomal lipid plateaued, the
decrease in the drug-to-lipid ratio in tissues reflects a
decrease in tissue DXR concentrations, presumably after it
has been released from liposomes. After release, DXR is
either cleared from the tissue or metabolized in situ to either
fluorescent or non-fluorescent forms; since this study did
not differentiate between the parent drug and metabolites, it
is not possible to say which process predominated. Hence,
data at the longer time points should be interpreted with
caution. In skin and paws, the tissue DXR elimination rates
(kelm) were of a similar magnitude for all three formulations
(Table 3). In tumor, however, the liposomes containing
DOPC showed a faster DXR elimination rate than the other
two formulations, indicating a faster rate of DXR release for
the DOPC-containing liposomes in the tumor-specific mi-
croenvironment. This is consistent with the faster DXR
release rate these liposomes showed in plasma.
For all liposomal formulations of DXR tested, DXR
elimination from tumor and cutaneous tissues was slower
than from plasma. DSPC:CHOL:mPEG-DSPE liposomes
had the best drug retention and produced the highest total
DXR AUC in tumor, as well as in cutaneous tissues. The
slow cutaneous clearance of DXR has potential implications
for the clinical use of CaelyxR. Cancer therapy is usually
administered in repeated cycles; if the dose interval is not
long enough to allow for complete elimination of DXR-
loaded liposomes from the skin, the drug may accumulate
and cutaneous toxicities will be more likely to occur. Recent
experimental data in the mouse model used here as well as
clinical evidence support this hypothesis, as prolonging the
dose interval reduces the incidence and severity of PPE
lesions [11].
Unexpectedly, liposomes composed of POPC:CHOL:
mPEG-DSPE (intermediate drug release rate) showed a highlevel of toxicity in therapeutic experiments. These lip-
osomes apparently produced sustained, cardiotoxic concen-
trations of bioavailable DXR, an assumption that was
supported by gross pathological observations. In contrast,
neither DSPC:CHOL:mPEG-DSPE nor DOPC:CHOL:
mPEG-DSPE liposomes showed gross signs of cardiac
toxicity. The slow rate of DXR release from the DSPC:
CHOL:mPEG-DSPE formulation and the rapid redistribu-
tion of DXR from the DOPC:CHOL:mPEG-DSPE formula-
tion into a large tissue volume of distribution may have
prevented the build-up of cardiotoxic drug concentrations in
the heart for these formulations. Thus, drug leakage rates are
important in determining the toxicity as well as the thera-
peutic activity of liposomal formulations. Administering
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tion with free DXR did not produce this toxicity, again
suggesting that the rate of drug release plays an essential
role in the development of this toxicity.
The bioavailability of the encapsulated drug is another
important concept to consider when interpreting these data.
Current thinking regarding the mechanism of action of
CaelyxR is that the liposomes accumulate in tumor and
slowly release their contents. This released and thus bio-
available drug then is able to exert its therapeutic activity. If
the concentration of bioavailable drug does not reach a
minimum cytotoxic concentration, then no appreciable ther-
apeutic response will be seen. This problem was encoun-
tered with a STEALTHR liposomal formulation of cisplatin
(SPI-077), which produced high tumor drug AUCs in
experimental models, but failed to produce correspondingly
high anti-tumor responses both in animal models and in
humans, so that its development was stopped in Phase II
clinical trials [43,44]. In the current study, administration of
DXR-loaded DSPC:CHOL:mPEG-DSPE liposomes yielded
not only a high total DXR concentration in tumor, but also
the best therapeutic activity of the formulations tested,
suggesting that drug was bioavailable at levels above the
minimum therapeutic dose.
In conclusion, our data demonstrate that drug leakage rates
play an important role in the therapeutic activity and the
toxicity of liposomal drug formulations. Solid liposomes
composed of DSPC:CHOL:mPEG-DPSE produced the high-
est total DXR concentration in all tissues of interest and had
the best therapeutic activity of the formulations tested. Even
though this formulation had the slowest rate of DXR leakage,
it produced cytotoxic concentrations of bioavailable drug in
tumor tissue in vivo, resulting in a good therapeutic effect.
The large values of cutaneous total DXR concentrations
obtained with DSPC:CHOL:mPEG-DPSE liposomes sug-
gest that PPE is a result of skin damage resulting from the
skin accumulation of liposomal DXR followed by the sus-
tained release of DXR in the skin. From these results, the
mouse appears to be an appropriate model in which to study
this phenomenon. In these studies, we were unable to
uncouple skin toxicity from therapeutic effect by manipulat-
ing the rate of drug release from the liposomes; in other
words, leakage rates that led to lower skin and paw levels of
DXR also resulted in reduced therapeutic effects.Acknowledgements
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